A humanized, plant-derived monoclonal antibody targeting the WNV envelope protein (Hu-E16) showed protective efficacy in mice, even when administered up to 4 days post-infection, offering a proof-of-concept for passive immunotherapy approaches (Lai et al., 2010). This evidence concerns the gene ERVW-1 and infection.